Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality

Prateek Sharma a,b, Tapan Behl a,*, Neelam Sharma a, Sukbir Singh a, Ajmer Singh Grewal c, Ali Albarrati d, Mohammed Albracht e, Abdulkarim M. Meraya f, Simona Bungau g,h,**

a Chitkara College of Pharmacy, Chitkara University, Punjab, India
b Government Pharmacy College, Nagrota Bagwan, Kangra, Himachal Pradesh, India
c Guru Gobind Singh College of Pharmacy, Yamuna Nagar, Haryana, India
d Rehabilitation Health Sciences, College of Applied Medical Sciences, King Saud University, Saudi Arabia
e Pharmacy Practice Research Unit, Department of Clinical Pharmacy, Jazan University, Jazan, Saudi Arabia
f Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia
h Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania

corresponding author.

** Corresponding author at: Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
E-mail addresses: tapanbehl31@gmail.com (T. Behl), simonabungau@gmail.com (S. Bungau).

Abstract

Diabetes is a condition that affects a large percentage of the population and it is the leading cause of a wide range of costly complications. Diabetes is linked to a multi-fold increase in mortality and when compared to non-diabetics, the intensity and prevalence of COVID-19 ailment among diabetic individuals are more. Since its discovery in Wuhan, COVID-19 has grown rapidly and shown a wide range of severity. Temperature, lymphopenia, non-productive cough, dyspnoea, and tiredness are recognized as the characteristic of individuals infected with COVID-19 disease. In COVID-19 patients, diabetes and other related comorbidities are substantial predictors of disease and mortality. According to a recent study, SARS-CoV-2 (the virus responsible for covid-19 disease) may also lead to direct pancreatic harm, which could aggravate hyperglycemia and potentially cause the establishment of diabetes in formerly non-diabetic individuals. This bidirectional association of COVID-19 and diabetes load the burden on health care professionals throughout the world. It is recommended that gliptin medications be taken moderately, blood glucose levels must be kept under control, ACE inhibitors should be used in moderation, decrease the number of avoidable hospitalizations, nutritional considerations, and some other prevention measures, such as immunization, are highly recommended. SARS-CoV-2 may cause pleiotropic changes in glucose homeostasis, which could exacerbate the pathophysiology of pre-existing diabetes or result in new disease processes.

1. Introduction

The severity of diabetes as a medical problem has risen considerably in the past two decades, making it a worldwide concern [1]. Diabetes afflicted 30 million people in 1985 and 285 million people in 2010. Globally, 700 million people are anticipated to be affected by diabetes by 2045. In 2019, 463 million people are affected by the disease [2,3]. End-stage renal failure, blindness, and lower-limb abnormalities are all linked to diabetes. There is a higher chance of getting life-threatening illnesses in those who are affected by these ailments [4,5].

The first pneumonia incidents of unknown origin were discovered in Wuhan in early December 2019, in Hubei Province, China. The SARS-associated coronavirus causes an acute respiratory tract disorder known as a severe acute respiratory syndrome (SARS). Coronavirus-2

**Abbreviations:** SARS-CoV-2, severe acute respiratory syndrome corona virus-2; COVID-19, corona virus disease-19; ACE2, Angiotensin-Converting Enzyme 2; T2D, type 2 diabetes; Plpro, papain-like protease; nsp3, non-structural protein 3; 3Clpro, 3C-like protease; S, spike protein; M, protein membrane; E, envelope protein; N, nucleocapsid protein; HE, hemagglutinin-esterase; MERS, Middle East respiratory syndrome; CDC, Centers for Disease Control and Prevention; RT-PCR, Reverse transcription polymerase chain reaction; IL-6, interleukin-6.
Biomedicine & Pharmacotherapy 151 (2022) 113089

2

P. Sharma et al.

2. Structure of SARS-CoV-2

This virus belongs to the family Coronaviridae and the genus Beta-coronavirus. Its RNA is single-stranded and positive-sense [30]. The size of the genome of this virus is approximately 29.9 kb, which was recently sequenced and has 78% biological (sequence) homology with SARS-CoV [30]. The SARS-CoV-2 genomic RNA, ORF1a and ORF1b includes 66% of the total genome and is translated into two different proteins namely pp1a and pp1b. A papain-like protease (PLPro), commonly referred to as nsp3 (non-structural protein 3), and a 3 C-like protease (3CLpro), also known as nsp5, are both encoded in the viral genome. Both these proteases cut the polypeptides pp1a and pp1b and generated sixteen non-structural proteins (nsp) [32,33]. Nsp12 is located in the midst of the RNA-dependent RNA polymerase and is essential for coronavirus replication and transcription. The nsp12 and template-primer RNA pairing was greatly boosted by nsp7 and nsp8 [29,34]. Residual 1/3rd of the genome is made up of overlapping ORFs that encode four important structural proteins: S, N, M, and E (spike glycoprotein, nucleocapsid protein, membrane protein, envelope protein), as well as other supplementary proteins [29,33–35]. The S1 subunit is comprised of two subdomain units namely SD1 and SD2, one receptor-binding domain commonly referred to as RBD, and a signal peptide commonly termed as SP. The Membrane-fusion subunit (S2) contains the heptad repeat 1, heptad repeat 2, transmembrane and fusion peptides also termed HR1, HR2, TM, and FP respectively [36]. Structural proteins E, along with M and N proteins are thought to aid in the formation of virus-like particles (Fig. 1) [37].

3. Incubation interval and mechanism of propagation

The interval between infection and the development of illness is described as the incubation period. The median incubation duration was 4 days in a group comprising 1099 Chinese patients with lab-confirmed symptomatic COVID-19. Another research with 181 confirmed cases found that the median incubation time was around 5 days and by the 12th day, 97.5% of infected patients had developed symptoms [37,38]. Depending on the incubation time of SARS-CoV and MERS-CoV, along with scientific data, the US CDC (Centers for Disease Control and Prevention) predicts COVID-19 symptoms to appear 2–14 days after infection. As a consequence, the international norms for monitoring and regulating the mobility of healthy persons have been set at fourteen days.

Most of the early patients of COVID-19 had previously been exposed to a Chinese seafood and animal market in their area, indicating that zoonotic exposure was the primary mechanism of transmission [39]. It has been discovered via viral genome sequencing that SARS-CoV-2 and the bat coronavirus may have shared an ancestral lineage, even though bats aren’t sold at this seafood market [40]. Following that, cases were reported in the medical community as well as in people who had no previous contact with animals or who had visited Wuhan, showing the transmission of the disease from person to person [39]. The virus is most often disseminated by direct touch, aerosol, and tiny particles. The virus may transmit to those around when pulmonary droplets from a COVID-19 patient or droplets from a sneeze or cough are swallowed or inhaled.

4. Diagnosis

COVID-19 cannot be diagnosed without a microbiologic
examination. As there is a limited capacity for screening for COVID-19 in reported incidents, specific criteria for priority patients may be specified by local health agencies. However, numerous testing methods have already been created, real-time fluorescence (RT-PCR) is the common model technique for coronavirus detection that identifies viruses in mucus, naso-oropharyngeal samples, and respiratory tract sputum [44].

5. What effect does diabetes mellitus have on COVID-19 and vice versa?

There are several plausible pathophysiological explanations for the connection between diabetes and the occurrence of coronavirus-19. As the main line of defense against this infection, a weakened body’s defensive system is seen in patients with uncontrolled diabetes [45]. Additionally, as demonstrated in COVID-19 sufferers, diabetes is a pro-inflammatory syndrome characterized by an improper and exaggerated cytokine response, where DM patients had significantly greater amounts of interleukin-6 (IL-6), ferritin, and C-reactive protein in their bloodstream compared non-DM individuals [46]. This demonstrates that individuals having unmanaged blood glucose levels are higher vulnerable to cytokine production outbursts, which consequently leads to rapid exacerbation of this devastating disease due to the development of ARDS and shock. Furthermore, preceding research found that COVID-19 subjects with diabetes mellitus had greater D-dimer values than those who did not have diabetes mellitus, probably indicating hemostatic system over-activation [46]. Hyper-activation of the coagulation cascade in COVID-19 in the context of a pre-existing pro-thrombotic hypercoagulable state exacerbated by the simple presence of DM may result in severe thromboembolic outcomes and eventual mortality [47, 48].

Diabetes mellitus is associated with decreased expression of angiotensin-converting enzyme 2 (ACE2), an enzyme found in the epithelial cells of alveoli, small intestine, vascular endothelium, and various other human organs. Under normal physiological conditions, ACE2 degrades angiotensin-II and, to a lesser degree, angiotensin-I into smaller peptides known as angiotensin (1–7) and angiotensin (1–9) respectively. Both ACE2 and Ang 1–7 have a beneficial effect in reversing inflammation and oxidative stress. Additionally, ACE2 has been found to protect against transmission of avian influenza A H5N1 [49]. As a consequence, the increased prevalence of ARDS and substantial lung damage associated with this catastrophic condition may be explained by decreased ACE2 expression in DM [50]. ACE inhibitors (ACEi) and angiotensin-receptor blockers have opposing effects that must be considered. ACEi/ARBs are often used as antihypertensive and renoprotective medicines in people with diabetes. Upregulation of ACE2 is connected to the use of ACEi/ARBs [51]. Ironically, for gaining entry into the recipient pneumocytes, coronavirus targets ACE2; hence enzyme overexpression would assist the coronavirus invasion and
subsequent proliferation. As a result, ACE2 is downregulated and fails to defend the lungs after the pathogen utilizes the enzyme to allow access to the host organism. Hemoglobin’s capacity to carry oxygenated blood may be impaired by the non-structural proteins of SARS-CoV-2, which target hemoglobin’s β1-chain, according to recent research. Coronavirus may have a stronger tendency for attacking glycated Hb to non-glycated Hb, although this is only a hypothesis [52].

Diabetes patients with COVID-19 had a less survival rate and a greater mortality rate than non-diabetic patients, according to various studies reported. Dey et al. reported in their first study on 53 old males, who already suffered from diabetes and hypertension. By following a low-glycemic diet and other lifestyle changes, the diabetic patient was successfully controlling his condition. On the 10th day after getting an infection of COVID-19, serious complications were noticed including diabetic ketoacidosis, hyperglycemic blood level, imbalanced sodium, urea, and potassium level. COVID-19 was detected in the second investigation, which found that a 78-year-old man had been hospitalized previously with the same symptoms. On the ninth day of illness, he got HHS with bilateral pneumonia. He was already taking medicines for diabetes and hypertension. Complications became more drastic for both diabetic patients with the progression over time [53]. Additionally, Maddaloni et al. investigated the risk by researching 79 diabetes patients admitted to hospital with covid-19 illness and 158 control diabetic patients without corona virus-19. COVID-19 diabetic patients were shown to have a greater chance of COPD and chronic kidney disease (CKD) [54]. In a meta-analysis of 128 types of research, Shrestha et al. found that 44.93% of the participants had diabetes and hyperglycemia as their primary concerns. The total mortality rate for the diabetic and hyperglycemic patients was found to be approximately triple i.e., 26.62% corresponding to non-diabetic patient (9.26%). The fatality rate was observed at 24.96% in COVID-19 associated diabetic patients. Moreover, the numbers of adverse events were also more in DM patient than in non-diabetic subjects [55]. Fawares et al. described a case study of a 46-year-old diabetic male patient with beginning physiological parameters that were virtually normal, but who developed DKA and AKI as a result of a growing imbalance in physiological parameters [56].

Table 1

| Sr. No. | Patient age (yrs) | Gender | Symptoms (COVID-19 infection) | Disease history | Medication history | Management of comorbid disease | Serious complications observed | Ref. |
|---------|------------------|--------|--------------------------------|----------------|-------------------|-------------------------------|-------------------------------|------|
| 1       | 53               | Male   | Tiredness, myalgia, dyspnea, and vomiting | Diabetes and hypertension | Nil               | Diet, exercise, and lifestyle modification | DKA, plasma blood glucose 1543 mg/dL, Glycated hemoglobin 13.0%, blood urea 32.10–136.9 mg/dL, Na: 139–164, mEq/L, K: 4.1–5.3 mEq/L, On 9th day of admission: Hyperosmolar hyperglycemic state (HHS), pulse 124 bpm, BP 180/100, blood glucose 626 mg/dL, blood urea 64 mg/dL, serum Na: 167 mEq/L, serum K 4.2 mEq/L, serum osmolality 378 mOsm/kg | [52] |
| 2       | 78               | Male   | Mild fever and dry cough       | Diabetes mellitus, hyperglycemia, and recurrent ischemic stroke | Statins, ARBs (losartan), and oral hypoglycemic agents | NA                           | NA                            | [53] |
| 3       | 46               | Male   | Weakness, myalgia, hypoxia, vomiting, polydipsia, polyuria | Diabetes and hypertension | Nil               | Diet, exercise, and lifestyle modification | Diabetic Ketoacidosis (DKA) and Acute Kidney Injury (AKI), thrombocytopenia, pneumonia, CRP 4.03–19.8 mg/ml, Na: 139–164 mEq/L, serum K: 4.1–5.3 mEq/L | [55] |

New on set of diabetes after COVID-19

| Sr. no. | Type of study | Mean Age (y) | Study population | Setting | Diabetic prevalence (%) | Ref. |
|---------|---------------|--------------|------------------|---------|-------------------------|------|
| 1       | Retrospective | 64           | 258              | West Court of Union Hospital in Wuhan, China | 24  | [59] |
| 2       |               | –            | 5279             | The single academic medical center, New York City | 22.6 | [62] |
| 3       |               | 61           | 453              | Wuhan Union Hospital | 11.7 | [63] |
| 4       |               | 47           | 80               | Anhui Provincial Hospital | 27.5 | [64] |
| 5       |               | 56           | 191              | Jinyintan Hospital and Wuhan Pulmonary Hospital | 19  | [65] |
| 6       |               | 62 and 53   | 7337             | The multi-centered study, Hubei Province, China | 13  | [66] |
| 7       |               | 66.6 and 68.5 | 59               | Vanvitelli University and San Sebastiano Caserta Hospital | 44  | [67] |

DKA, Diabetic Ketoacidosis; HHS, Hyperosmolar hyperglycemic state; BP, Blood Pressure; AKI, Acute Kidney Injury; ARBs, Angiotensin receptor blocker; Na, Sodium; K, Potassium; mg/dL, milligram per deciliter; mEq/L, Mill equivalents per liter.
Leon-Abarca JA et al. looked at the medical records of adult Mexican patients aged 20–90 who reported COVID-19-like symptoms in the previous week. The presence of DM was identified in 12.97% of the total number of records. According to the findings, diabetes patients were more likely to contract COVID-19 and develop pneumonia [57]. Liu Z et al. carried out a retrospective observational study for a large sample group (1880 patients). In contrast to earlier research with high sample sizes, the findings revealed contradictory observations that diabetes had no meaningful impact on COVID-19 patients’ prognosis but had a detrimental impact on their clinical course [58]. A retrospective cohort study was performed on 258 COVID-19 hospitalized patients (diabetic patient 63) by Zhang Y et al. Diabetic patients had substantially higher leukocyte and neutrophil counts, as well as greater fasting blood sugar, creatinine levels, and other important biological markers when hospitalized in contrast to individuals without diabetes. COVID-19 individuals were shown to have a high prevalence of diabetes (24%) [59].

Kumar A et al. analyzed 33 studies in their meta-analysis (16,003 patients). Diabetes was shown to be prevalent in 9.8% of covid-19 patients. Diabetes has been linked to a twofold rise in mortality and COVID-19 intensity corresponding to the euglycemic patient [60]. Li B et al. conducted a meta-analysis of six Chinese research (no. of patients 1527) and observed the prevalence of diabetes was found to be 9.7% [61]. COVID-19 individuals were studied in a retrospective cohort study from New York City by Petrilli et al. Altered blood glucose levels and overweight were more prevalent in hospitalized patients than in non-hospitalized patients (Table 1) [62]. COVID-19 diabetics have a poor prognosis, but newer research has linked it to the emergence of new-onset diabetes as well.

6. Exacerbation of inflammatory storm in diabetes

People with diabetes often have some degree of chronic inflammation, which may lead to cytokine storms and the death-causing consequences of COVID-19 [13,68]. Guo et al. presented the first study of biochemical characteristics of diabetic COVID-19 persons, indicating that diabetic individuals have a significantly fewer amount of lymphocytes than non-diabetic people, while the number of neutrophils is considerably greater. In further retrospective investigations assessing the clinical parameters of COVID-19 diabetic and non-diabetic patients, elevated NLR, procalcitonin (PCT), and high-sensitivity C response protein (CRP) were also found [46]. Certain inflammation-related indicators were also enhanced in diabetes individuals, with interleukin (IL)–6 being the most elevated among the different markers [69,70]. Elevated NLR and CRP among COVID-19 individuals along with elevated inflammatory biomarkers were shown to be independent risk factors for disastrous outcomes [70,71]. Furthermore, preliminary research indicates that tocilizumab which targets IL-6 could enhance COVID-19 therapy. Activation of the monocyte-macrophage cascade is shown by a significant increase in blood protein (ferritin), which is a key component of the cytokine storm. As a result, these findings suggest that patients with diabetes are more likely to trigger an inflammatory storm, resulting in fast COVID-19 precipitation (Fig. 3) [72–74].

7. Relationship between COVID-19 and diabetes mellitus

Chronic diabetes and uncontrolled blood sugar levels are substantial risk factors in people who have been infected by several viruses [75–77]. COVID-19 infection and mortality were more common in older individuals with chronic diseases like diabetes, according to various reports published worldwide. In COVID-19 people, there is much less data on glucose homeostasis and the establishment of acute diabetic complications such as ketoacidosis. COVID-19 diabetics may result in increased stress levels and the production of hormones (glucocorticoids and catecholamines) which elevate the blood sugar content and improper glucose fluctuation [78]. Retrospective research from Wuhan, on the other hand, revealed that almost 10% of COVID-19 diabetics had a minimum single hypoglycemic episode [64]. The activation of pro-inflammatory monocyte and the activation of platelets have been

---

**Fig. 3.** The effects of COVID-19 on pancreatic β-cells have been studied. SARS-COV-2 causes the downregulation of ACE2, which is located over β-cells, increasing cytokine storm and fibrosis of the pancreas, as well as a reduction in pancreatic blood flow and insulin secretion, all of which contribute to decreased pancreas survival and severity of disease progression in the patient. ACE2, Angiotensin-converting enzyme 2; Ang 1–7, Angiotensin 1–7; AT1R, Angiotensin II receptor type 1; SARS-COV-2, severe acute respiratory syndrome corona virus-2.
related to reducing blood glucose levels, all of which have been linked to a greater cardiovascular risk in diabetic patients [79]. Despite this, little is known about the mechanisms through which these individuals’ inflammatory and immunological responses function, if hyper or hypoglycemia affects virus pathogenicity, or whether the virus has an effect on insulin release or blood glucose control. Diabetes mellitus is a chronic inflammatory disease that causes lots of new metabolic and vascular issues that might make it difficult to fight infections. Additional production of AGEs, interleukins, and tissue necrosis factor (pro-inflammatory cytokines), as well as oxidative stress that drives tissue inflammation, are all promoted by hyperglycemia and insulin resistance. This inflammatory process might be the underlying cause of greater susceptibility to infections, as well as worse infection results in diabetic individuals [80,81].

There have been several links established between immune system deficits and hyperglycemia, but the clinical relevance of various in vitro modifications is still up in the air [82]. Diabetes that is poorly managed has been connected to a reduced lymphocyte proliferation in response to a variety of sensory stimuli and additionally modified phagocyte responses [83]. Atypical impeded hypersensitivity response and complement proteins stimulation-related abnormalities were documented among diabetics [82,84]. In vitro experiments have demonstrated that high sugar levels promote influenza virus infection and replication in pulmonary epithelial cells, indicating that high glycemic content in the blood may enhance viral replication in vivo as well [85]. Experiments on animals have indicated that structural lung changes such as increased blood vessel permeability and collapsed pulmonary epithelium are associated with diabetes [86]. Diabetic patients, on the other hand, have a considerable decrease in pulmonary function tests which is linked to elevated glycemic content in plasma [87].

8. Treatment for COVID-19 diabetes patients

In diabetics with COVID-19 infection, regular monitoring of blood glucose levels is important, both during hospitalization and quarantine [88]. Maximum mild infections should be handled as normal, except for inhibitors of the sodium-glucose cotransporter-2 which may lead to higher rates of dehydration and diabetic ketoacidosis and necessitate cautious renal function surveillance. Metformin has been associated with lactic acidosis, hence it is recommended that patients with moderate or severe illness discontinue taking it while receiving hospital treatment. Oral hypoglycemic drug (Sulfonylurea) dosage modifications should be made following patient sugar levels, limited food intake, and the danger of hypoglycemia. In addition, discontinuation is highly advocated in hospitalized patients [89]. Since the usage of dipeptidyl peptidase-4 inhibitors has been associated with a higher risk of upper respiratory tract infections (RTIs), they do not reduce the risk of pneumonia and there is little evidence in favor or opposition regarding their usage [90]. Considering the notion that insulin usage in COVID-19 diabetics is linked to poor consequences, insulin treatment appears to remain a preferred option for hospitalized sick people. All oral anti-diabetic medications should be stopped in hospitalized patients. Depending on the specific therapy strategy, insulin dosages may need to be changed. For quick hyperglycemia treatment, fast-acting insulin is employed in individuals who receive basal insulin; blood glucose variation following insulin treatment necessitates vigilant and continuous monitoring [89]. In a retrospective, multicenter trial in China, when compared to improperly managed patients, effective glucose level control (glycemic index 3.9–10.0 mmol/L) has been linked to a lower risk of death [66]. In COVID-19 diabetic patients admitted to the ICU, the most pressing challenges are maintaining proper glycemic control and managing the high insulin requirements. Intravenous steroids, vitamin C, or other drug prescriptions may all lead to increased glucose fluctuation. Depending on the treatment strategy, the physician should choose the most appropriate customized insulin regimen [91]. Hydroxychloroquine has been reported to lower viral load and glycated hemoglobin (HbA1c) in several countries as COVID-19 infection prevention [92]. Hydroxychloroquine, on the other hand, may induce hypoglycemia. Furthermore, hydroxychloroquine in conjunction with metformin has the potential to be hazardous [93]. Despite the positive effects of hydroxychloroquine on glycemic management; long-term treatment in diabetic individuals has been linked to CVS issues and vision problems. Using hydroxychloroquine in individuals with diabetes and COVID-19 may cause severe ventricular arrhythmias, particularly when taken with medications that lengthen the QT interval of ECG [94].

9. Immunization in diabetes patients against COVID-19

Type 2 diabetics have a greater risk of morbidity and death from COVID-19 disease. As a consequence, coronavirus disease 2019 causes higher hospital readmission rates and severity of illness in patients with T2D [95]. Furthermore, a patient’s prognosis with COVID-19 is worsened by poor glycemic management, which increases the likelihood of ICU treatment due to mechanical resuscitation, trauma, and multi-organ failure [95]. The importance of timely and proper immunization in the primary prevention of disease cannot be underscored. Pneumococcal pneumonia immunization is recommended regularly and other viral diseases are suggested for people having diabetes [96]. Even though past research has shown that people with uncontrolled diabetes had reduced antibody responses to several viral vaccinations [97,98]. Because of recent advancements in vaccine manufacture, patients with diabetes who get vaccinations may now establish a normal immune response. The effectiveness and safety of pneumococcal vaccination have been found to range from 56% to 81% in numerous case-control studies [99,100]. In people with diabetes, the side effects of immunization are typically minor. 1568 diabetic patients were vaccinated against pneumonia and influenza at an Indian diabetes clinic. Only joint and muscular discomfort, fever, local rash, and enlarged glands were reported as adverse effects. There were no serious allergic responses recorded. Only 17 out of 2057 DM patients who had pneumococcal vaccines reported slight injection site pain or redness [99]. Several COVID-19 vaccinations have been produced, each with varied effectiveness and safety. Vaccines like BNT162b2 (developed by Pfizer-BioNTechUSA, Germany), mRNA-1273 (developed by Moderna, USA), AZD1222 (ChAdOx1) (developed by Oxford-AstraZeneca Jenner Institute), Sputnik V (developed by Gamaleya Research Institute of Epidemiology and Microbiology Russia), NVX-CoV2373 (developed by Novavax, Inc. USA), CoronaVac (developed by Inovac Biotech China), JNJ-78436735 or Ad26. COV2. S (developed by Johnson & Johnson (Janssen Biotech, Inc., USA)), Covaxin (invented by Bharat Biotech India), Covishield (invented by Serum Institute, Pune, India) [101–107]. Efficacy of these vaccines was found to be reported at 50.65–95%. Overweight, CVD, pulmonary illness, and diabetes were among the comorbidities evaluated in the clinical studies [108].

10. Diabetes treatment for non-infected individuals

Since diabetes management has been shown to have a detrimental impact on prognosis and increase the chance of infection hence during the COVID-19 epidemic, tight glucose management is essential [109]. Prevention plans that work often involve things like social isolation and thorough cleaning [73]. However, such limits on travel and quarantine should not compromise the availability of effective healthcare services. As a consequence, during the era of this devastating disease, access to healthcare practitioners should be assured [109]. As a result, telehealth services might be a cost-effective way to interact with patients or perhaps identify possible diabetic complications in the early stage, such as indicators of blood glucose dysregulation or infection. Patients should also receive adequate medicine and a glucose assay kit for usage at home. In certain circumstances, access to social care specialists may be required, given the importance of stress management for mental and physical health stability [109,110]. There is insufficient evidence to
recommend discontinuing hypertension, diabetes, or dyslipidemia drugs; frequent use of anti-diabetic medicines and insulin is recommended [73]. Despite various theories indicating that long-term use of ACE inhibitors and ARBs may enhance the likelihood and severity of infection due to COVID-19 disease, the European Council on Hypertension (ESC Council) strongly advises that patients continue to use their routine hypertension drugs since there is no evidence that they are harmful. The clinical outcomes of ACEi/ARBs in patients with diabetes and hypertension who have COVID-19 were similar to those in the control group, according to a recent study. A healthy lifestyle is required to maintain great glycemic control that includes a balanced diet, frequent cardiovascular activity, and low-weight resistance training [111,112].

11. Conclusion and future directions

Diabetes mellitus is a leading cause of a cascade of costly complications, when it strikes young people, it may drive them out of work. Furthermore, COVID-19 illness is a severe respiratory disorder and its virus spreads through the globe, infecting and killing millions of individuals. Symptoms of COVID-19 include throat infection, temperature, non-productive cough, lethargy, and diarrhea in all patients. Uncontrolled glucose level is linked to a rise in the intensity of COVID-19 sickness. Pathophysiology, on the other hand, remains unclear. Recognizing the link between COVID-19 and diabetes might lead to therapeutic clinical interventions, however, evidence is scarce on the subject. According to the data, diabetes must always be regarded as a major cause of the severity of COVID-19 symptoms and the ideal function is to lower the exposure to corona sources. Healthcare systems must design programs to reduce diabetes patients’ exposure to the risk of disease [113–115, 64]. Prompt quarantine, diagnosis, and treatment may all aid in the control of the disease and improve the result. In COVID-19 patients, unmanaged glycemic content and other degenerative diseases are major determinants of illness and death. Diabetes and COVID-19 are two diseases that have a global impact. Approximate 14.5% of COVID-19 patients had diabetes, placing them at greater risk for the severity and lethality of COVID-19. Prevention is the best function, followed by the use of evidence-based therapies. Gliptin medicines should be used in programs to reduce diabetes patients’ exposure to the risk of disease [111,112].

Declaration of Interest

There is no conflict of interest in the submission of the manuscript.

Data availability

No data was used for the research described in the article.

References

[1] A. Ramachandran, C. Snehalatha, A.S. Shetty, A. Nanditha, Trends in prevalence of diabetes in Asian countries, World J. Diabetes 3 (2012) 110–117, https://doi.org/10.4239/wjd.v3i6.110.
[2] J.E. Shaw, R.A. Sicree, P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030, Diabetes Res Clin. Pr. 87 (2010) 4–14, https://doi.org/10.1016/j.diabres.2009.10.007.
[3] A.S. Grewal, V. Lather, N. Charaya, N. Sharma, S. Singh, V. Kairys, Recent developments in medicinal chemistry of allosteric activators of human glukokinase for type 2 diabetes mellitus therapeutics, Curr. Pharm. Des. 26 (2020) 2510–2552, https://doi.org/10.2174/138161282666664014163148.
[4] P. Sharma, S. Singh, V. Thakur, N. Sharma, A.S. Grewal, Novel and emerging therapeutic drug targets for management of type 2 diabetes mellitus, Obes. Med. 24 (2020) 100329, https://doi.org/10.1016/j.obrmed.2020.100329.
[5] A.S. Grewal, B.S. Sekhon, V. Lather, Recent updates on glukokinase activators for the treatment of type 2 diabetes mellitus, Mini Rev. Med. Chem. 14 (2014) 585–602, https://doi.org/10.2174/13895575146666401412082713.
[6] M. Chan-Yeung, R.H. Xu, SARS: epidemiology, Respiriology 8 (2003) S9–S14, https://doi.org/10.1140/1444-1843/2003.00518.-a.
[7] J. Cui, F. Li, Z.L. Shi, Origin and evolution of pathogenic coronaviruses, Nat. Rev. Microbiol. 17 (2019) 181–192, https://doi.org/10.1038/s41579-018-0118-9,
[8] S. Su, G.K. Wong, W. Li, D.W. Li, T. Li, Y. Li, Y.B. Gu, et al., Early detection of severe acute respiratory syndrome coronavirus 2 in patients with mild respiratory illness, Lancet 395 (2020) 207–213, https://doi.org/10.1016/S0140-6736(20)30530-1.
[9] D. Harsner, M. Gilbert, R. Borman, K.L. Clark, Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme, FERB: Lett. 532 (2002) 107–110, https://doi.org/10.1016/S0014-579X(02)03064-0.
[10] Y.C. Li, W.Z. Bai, T. Hashikawa, Response to Commentary on “The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients”, J. Med Virol. 92 (2020) 707–709, https://doi.org/10.1002/jmv.25824.
[11] N.W. Palm, R. Medzhitov, Not so fast: adaptive suppression of innate immunity, Nat. Med. 13 (2007) 1142–1144, https://doi.org/10.1038/nm1142b.
[12] P. Mehra, D.P. McAuley, M. Brown, E. Sanchez, R.S. Tattersall, J.I. Manson, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet 395 (2020) 1033–1034, https://doi.org/10.1016/S0140-6736(20)30628-0.
[13] H. Kafshidi, S. Abbas, A. Khan, T. Kaami, Z. Nazir, T. Aldaham, The clinical characteristics and outcomes of COVID-19 infections in patients with diabetes at a tertiary care center in the UAE, Dubai Diabetes Endocrinol. J. 26 (2021) 1–6, https://doi.org/10.1159/000521232.
[14] H. Li, S. Tian, T. Chen, Z. Cui, N. Shi, X. Zhong, K. Qiu, J. Zhang, T. Zeng, L. Chen, J. Zhen, Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19, Diabetes ObesMetab 22 (2020) 1897–1906, https://doi.org/10.1111/dom.14099.
[15] E. Barron, C. Bakhai, P. Kar, A. Weaver, D. Bradley, H. Ismail, P. Knighton, N. Holman, K. Khunti, N. Sattar, N. Wareham, B. Young, J. Valabhji, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol. 8 (2020) 813–822, https://doi.org/10.1016/S2213-8587(20)30527-9.
[16] Q. Shi, X. Zhang, F. Jiang, X. Zhang, N. Hu, C. Bimis, J. Feng, S. Yan, Y. Guan, D. Xu, G. He, C. Chen, X. Xiong, L. Liu, H. Li, J. Tao, Z. Peng, W. Wang, Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study, Diabetes Care 43 (2020) 1382–1391, https://doi.org/10.2337/dc20-0598.
[17] N. Holman, P. Knighton, P. Kar, J. O’Keeffe, M. Curley, A. Weaver, E. Barron, C. Bakhai, K. Khunti, N.J. Wareham, N. Sattar, B. Young, J. Valabhji, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol 8:263–263. https://doi.org/10.2173/218138587202007210.
[18] R. Lu, X. Zhan, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W.J. Liu, D. Wang, W. Xu, E. C. Holmes, G.F. Gao, G. Wu, W. Chen, C. Shi, W. Shi, W. Tan, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet 395 (2020) 564–570, https://doi.org/10.1016/S0140-6736(20)30251-8.
[19] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, G. Xue, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Zhao, L. Guo, X. Xie, G. Wang, B. Jiang, Z. Gao, Q. Jin, J. Wang, B. Yang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2019) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5.

Funding

Funds for the publication of this paper are provided by University of Oradea, Oradea, Romania, by an Internal project.

CRediT authorship contribution statement

Prateek Sharma, Tapan Behl, Neelam Sharma, Sukhbir Singh: Conceived the idea and wrote the article. Ajmer Singh Grewal, Ali Albarati: Literature review. Mohammed Albratty, Abdulkarim M. Meraya: Figure work. Simona Bungau: Proof read.
E. Bosi, L. Piemonti, Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study, Diabetologia 63 (2020) 2548–2558, https://doi.org/10.1007/s00125-020-05284-4.

[108] WHO, Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™). World Health Organization, 2021. (https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222–2021.1Accessed) 15 January 2022.

[109] C. Kosinski, A. Zanchi, A. Wojtusciszyn, Diabetes and COVID-19 infection, Rev. Med. 16 (2020) 939–943.

[110] A.M. Angelidi, M.J. Belanger, C.S. Mantzoros, Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next, Metabolism 107 (2020), 154245, https://doi.org/10.1016/j.metabol.2020.154245.

[111] G. de Simone, Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers, Eur. Soc. Cardiol. (2020) 13.

[112] Y. Chen, D. Yang, B. Cheng, J. Chen, A. Peng, C. Yang, C. Liu, M. Xiong, A. Deng, Y. Zhang, L. Zheng, K. Huang, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care 43 (2020) 1399–1407, https://doi.org/10.2337/dc20-0666.

[113] Y.J. Cheng, A.M. Kanaya, M.B.G. Araneta, S.H. Saydah, H.S. Kahn, E.W. Gregg, W.Y. Fujimoto, G. Imperatore, Prevalence of diabetes by race and ethnicity in the United States, 2011-2016, JAMA 322 (2019) 2389–2398, https://doi.org/10.1001/jama.2019.19365.

[114] E.S. Kim, B.S. Chin, C.K. Kang, N.J. Kim, Y.M. Kang, J.P. Choi, D.H. Oh, J.H. Kim, B. Koh, S.E. Kim, N.R. Yun, J.H. Lee, J.Y. Kim, Y. Kim, J.H. Bang, K.H. Song, H.B. Kim, K.H. Chung, M.D. Oh, Korea National Committee for Clinical Management of COVID-19. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19, J. Korean Med Sci. 35 (2020), e142, https://doi.org/10.3346/jkms.2020.35.e142.

[115] K.A. Kulcsar, C.M. Coleman, S.E. Beck, M.B. Frieman, Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, JCI Insight 4 (2019), e131774, https://doi.org/10.1172/jci.insight.131774.